Search Results - Endovascular Today

evt | Article | June 2024 Supplement

Limitations of Existing Embolic Protection Methods

With Ralf Langhoff, MD

evt | Article | Europe May 2015 Supplement

Expert Opinion on When to Use DCBs

By Ralf Langhoff, MD

evt | Article | September 2018 Supplement

The Importance of Vessel Preparation

Properly preparing lesions before use of drug-eluting technologies has become a crucial step of the treatment algorithm.

By Ralf Langhoff, MD

evt | Article | January 2025

Roundtable Discussion on the Current State of Atherectomy for Lower Extremity Arterial Disease

With Jeffrey Carr, MD; Ralf Langhoff, MD; and Eric A. Secemsky, MD, MSc

Sponsored by Boston Scientific Corporation

evt | Article | May 2019 Supplement

Roundtable Discussion: The Evolution of the CLI Treatment Algorithm

A multidisciplinary panel shares insights on practice patterns, treatment algorithms, and hopes for future solutions for this challenging disease.

With Ralf Langhoff, MD; Robert A. Lookstein, MD; Miguel Montero-Baker, MD; and Jihad A. Mustapha, MD, FACC, FSCAI

evt | Article | May 2017

VascuFlex® Multi-LOC: Spot Stenting With SeQuent® Please OTW DCB

Realizing the concept of leave-less-behind after DCB angioplasty in atherosclerotic lesions of the femoropopliteal artery.

By Klaus Amendt, MD, and Ralf Langhoff, MD

evt | News | April 22, 2021

1-Year Data Published for B. Braun’s SeQuent Please OTW DCB

April 22, 2021—One-year findings from the CONSEQUENT ALL COMERS observational study demonstrating low target lesion revascularization (TLR) and mortality rates for the SeQuent Please over-the-wire (OTW) drug-coated balloon (DCB; B. Braun Melsungen AG) in an unselected patient population were published by Principal Investigator Ralf Langhoff, MD, et al online in Angiology. Earlier this year, the data were presented at LINC 2021, the Leipzig Interventional Course, which was held virtually.

evt | News | February 12, 2021

Real-World CONSEQUENT Data Presented for B. Braun’s SeQuent Please OTW DCB

February 12, 2021—B. Braun Melsungen AG announced that the 1-year findings of the CONSEQUENT all-comers observational study of the company’s SeQuent Please over-the-wire (OTW) paclitaxel drug-coated balloon (DCB) demonstrated low target lesion revascularization (TLR) and mortality rates.

evt | Article | September 2020

Drug-Coated Balloon Update: Are All DCBs the Same?

A summary of presentations on the use of DCBs and treatment of complex lesions from the inaugural iVS.

With Fabrizio Fanelli, MD, EBIR; Prof. Ulf Teichgräber, MD; and Koen Deloose, MD

evt | News | October 1, 2017

Contego Medical Initiates ENTRAP Study of Vanguard IEP Peripheral Balloon Angioplasty System

October 2, 2017—Contego Medical, LLC recently announced the initiation of the ENTRAP study evaluating use of its Vanguard IEP peripheral balloon angioplasty system, with the company's integrated embolic protection (IEP) technology, in patients undergo peripheral angioplasty.

evt | News | May 20, 2018

First Procedure in Asia Performed With B. Braun's VascuFlex Multi-Loc Multiple Stent Delivery System

May 21, 2018—B.

evt | News | November 14, 2022

Contego’s Neuroguard IEP PERFORMANCE II Carotid Stent Trial Completes Enrollment

November 14, 2022—Contego Medical, Inc. announced that enrollment of the PERFORMANCE II clinical trial has been completed.

evt | News | June 5, 2023

Biotronik’s Oscar Multifunctional Peripheral Catheter Begins Commercial Launch

June 5, 2023—Biotronik announced the limited release of its Oscar (“One Solution: Cross.

evt | News | July 19, 2016

European Postmarket Registry for Contego Medical's Paladin Carotid System Completes Enrollment

July 20, 2016—Contego Medical, LLC announced it has completed enrollment in the Paladin carotid postdilation balloon system registry in Europe.

evt | News | December 19, 2024

Contego’s Neuroguard IEP System Used in First Commercial Procedures

December 19, 2024—Contego Medical announced the first commercial procedures were performed with the company’s Neuroguard IEP system.

evt | News | January 25, 2016

Data Presented at LINC for Contego Medical's Paladin System

January 26, 2016—Contego Medical announced the presentation of positive postmarket registry data for the Paladin carotid postdilation balloon with the company’s Integrated Embolic Protection technology at LINC 2016, the Leipzig Interventional Course, being held January 26–29 in Leipzig, Germany.

evt | News | March 13, 2026

Three-Year Neuroguard IEP PERFORMANCE II Data Presented

March 13, 2026—Three-year outcomes from the PERFORMANCE II trial studying the Neuroguard Integrated Embolic Protection (IEP) 3-in-1 Carotid Stent System were presented by William A. Gray, MD, at the International Symposium on Endovascular Therapy (ISET).